ResoTher Pharma, a Denmark-based biotech company, announced on Monday that it has received a EUR2.5m grant from the European Innovation Council (EIC).
The funds are intended to support the development of the company's Lead Compound, RTP-026, in a Phase 2a clinical study in Myocardial Infarction.
The project focusing on development of Resother Pharmas RTP-026 compound is one of 47 projects selected to receive funding out of 648 full proposals submitted for evaluation to the EIC-accelerator program. The grant given to ResoTher Pharma is defined as a 'Grant first,' meaning that the project will be considered for further support by the European Investment Bank upon completion of the Phase 2a study supported by the current grant.
RTP-026 is being developed as a new and innovative way to moderate the inflammatory response that occurs in the heart during the recovery phase of a myocardial infarction.
Nektar Therapeutics showcases rezpegaldesleukin at EADV 2024
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Pfizer names new Regional President for Middle East, Russia and Africa
GSK's Nucala approved in Japan for chronic rhinosinusitis with nasal polyps
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
Lipella launches OLP Patient Registry to advance research
Talphera enrols first subject in NEPHRO CRRT study
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults
Cantargia reports positive CAN10 trial data
Quoin Pharmaceuticals to study QRX003 for Peeling Skin Syndrome
Dragonfly Therapeutics names new chief financial officer
Formosa Pharmaceuticals secures exclusive Canadian licensing deal with Apotex
Bio-Techne invests in Spear Bio to boost ultra-sensitive immunoassay development